Silverback Therapeutics Stock Price Prediction
SPRY Stock | 13.48 0.91 7.24% |
Oversold Vs Overbought
37
Oversold | Overbought |
EPS Estimate Next Quarter (0.25) | EPS Estimate Current Year (0.55) | EPS Estimate Next Year (0.36) | Wall Street Target Price 27.25 | EPS Estimate Current Quarter (0.15) |
Using Silverback Therapeutics hype-based prediction, you can estimate the value of Silverback Therapeutics from the perspective of Silverback Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Silverback Therapeutics using Silverback Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Silverback using crowd psychology based on the activity and movement of Silverback Therapeutics' stock price.
Silverback Therapeutics Implied Volatility | 1.31 |
Silverback Therapeutics' implied volatility exposes the market's sentiment of Silverback Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Silverback Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Silverback Therapeutics stock will not fluctuate a lot when Silverback Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Silverback Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Silverback because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Silverback Therapeutics after-hype prediction price | USD 12.99 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Silverback contract
Based on the Rule 16, the options market is currently suggesting that Silverback Therapeutics will have an average daily up or down price movement of about 0.0819% per day over the life of the 2025-03-21 option contract. With Silverback Therapeutics trading at USD 13.48, that is roughly USD 0.011 . If you think that the market is fully incorporating Silverback Therapeutics' daily price movement you should consider acquiring Silverback Therapeutics options at the current volatility level of 1.31%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Silverback |
Silverback Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Silverback Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Silverback Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Silverback Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Silverback Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Silverback Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Silverback Therapeutics' historical news coverage. Silverback Therapeutics' after-hype downside and upside margins for the prediction period are 9.23 and 16.75, respectively. We have considered Silverback Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Silverback Therapeutics is not too volatile at this time. Analysis and calculation of next after-hype price of Silverback Therapeutics is based on 3 months time horizon.
Silverback Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Silverback Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Silverback Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Silverback Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.21 | 3.86 | 0.01 | 0.06 | 11 Events / Month | 8 Events / Month | In about 11 days |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
13.48 | 12.99 | 0.08 |
|
Silverback Therapeutics Hype Timeline
Silverback Therapeutics is at this time traded for 13.48. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.06. Silverback is projected to decline in value after the next headline, with the price expected to drop to 12.99. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.08%, whereas the daily expected return is at this time at -0.21%. The volatility of related hype on Silverback Therapeutics is about 1282.39%, with the expected price after the next announcement by competition of 13.42. About 23.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.5. Silverback Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 11 days. Check out Silverback Therapeutics Basic Forecasting Models to cross-verify your projections.Silverback Therapeutics Related Hype Analysis
Having access to credible news sources related to Silverback Therapeutics' direct competition is more important than ever and may enhance your ability to predict Silverback Therapeutics' future price movements. Getting to know how Silverback Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Silverback Therapeutics may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
NUVL | Nuvalent | (0.38) | 9 per month | 0.00 | (0.19) | 2.60 | (5.28) | 11.10 | |
ACLX | Arcellx | 1.38 | 10 per month | 0.00 | (0.11) | 5.73 | (6.79) | 16.73 | |
PCVX | Vaxcyte | (2.71) | 9 per month | 0.00 | (0.13) | 3.57 | (5.61) | 15.90 | |
CRNX | Crinetics Pharmaceuticals | 1.14 | 7 per month | 0.00 | (0.14) | 3.10 | (7.53) | 24.78 | |
CYTK | Cytokinetics | (0.23) | 9 per month | 0.00 | (0.11) | 3.83 | (3.46) | 13.86 | |
GPCR | Structure Therapeutics American | (2.40) | 8 per month | 0.00 | (0.09) | 7.41 | (7.98) | 22.37 | |
PLRX | Pliant Therapeutics | (0.1) | 7 per month | 0.00 | (0.06) | 5.37 | (5.67) | 20.55 | |
SNDX | Syndax Pharmaceuticals | (0.17) | 10 per month | 0.00 | (0.13) | 3.98 | (5.34) | 34.00 | |
RVMD | Revolution Medicines | 0.81 | 10 per month | 0.00 | (0.10) | 4.11 | (5.94) | 16.40 | |
INZY | Inozyme Pharma | (0.35) | 8 per month | 0.00 | (0.33) | 6.41 | (8.75) | 38.13 |
Silverback Therapeutics Additional Predictive Modules
Most predictive techniques to examine Silverback price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Silverback using various technical indicators. When you analyze Silverback charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Silverback Therapeutics Predictive Indicators
The successful prediction of Silverback Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Silverback Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Silverback Therapeutics based on analysis of Silverback Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Silverback Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Silverback Therapeutics's related companies. 2024 | 2025 (projected) | Graham Number | 5.02 | 3.46 | Receivables Turnover | 0.0434 | 0.0412 |
Story Coverage note for Silverback Therapeutics
The number of cover stories for Silverback Therapeutics depends on current market conditions and Silverback Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Silverback Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Silverback Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Silverback Therapeutics Short Properties
Silverback Therapeutics' future price predictability will typically decrease when Silverback Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Silverback Therapeutics often depends not only on the future outlook of the potential Silverback Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Silverback Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 95.2 M | |
Cash And Short Term Investments | 228.4 M | |
Shares Float | 45 M |
Additional Tools for Silverback Stock Analysis
When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.